1Havel R J. Rgulation of lipoprotein metabolism by lipoprotein receptors[J]. Atheroseler Rev, 1998,17 (1) : 1-8.
2Choi S Y, Fong L G, Kirven M J,et al. Use of an antiLDL receptor antibody to quantity the role of the LDL receptor in removal of chylomicron-remnant in the mouse in vivo[J]. J Clin Invest,1996,88(10) :1173-1181.
3Szanto A,Balasubramaniam S,Roach P D,et al . Modulation of LDL receptor related protein and its relevance to chylomicronremnant metabolism[J]. Biochem J, 1998,46(7) : 791-794.
4Todd P A. Goa K L. Fluvastatin: A Review of its pharmacological properties and therapeutic potential in hypercholesterolaemia[J]. Drug, 1990,40(5) : 583-607.
5Evans A J, Huff M W,Wlfe B M. Accumulation of an apoE-poor subfraction of very low density lipoprotein in hypertigly ceridemic men[J]. J Lipid Res, 1999,30(11) : 1671-1701.
6Reddick R L, Zhang S H, Maeda N. Atherosclerosis in mice lacking apoE. Evaluation of lesion development and progression[J]. Arterioscler Thromb, 1998,14(2): 141-147.
7Saku K J,Zhang B,Ohta T K, et al . Quantity and function of high density lipoprotein as an indictor of coronarya therosclerosis[J]. J Am Coll Cardiol, 1999,33 (8) : 340-443.
